At BELLUS, we are focused on developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. Read More

In November 2018, BELLUS announced the positive top-line results from the clinical Phase 1 study for BLU-5937, its lead drug candidate for chronic cough. Read More

Share this

Sign up for email alerts

Email Address *
 
Enter the code shown above.